Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IOBT Stock Forecast 2025-2026
$1.30
Current Price
$85.65M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IOBT Price Targets
+976.9%
To High Target of $14.00
+592.3%
To Median Target of $9.00
+361.5%
To Low Target of $6.00
IOBT Price Momentum
-13.3%
1 Week Change
+25.0%
1 Month Change
+4.0%
1 Year Change
+41.3%
Year-to-Date Change
-24.9%
From 52W High of $1.73
+97.0%
From 52W Low of $0.66
📊 TOP ANALYST CALLS
Did IOBT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IO Biotech is one of their latest high-conviction picks.
Latest IOBT Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, IOBT has a bullish consensus with a median price target of $9.00 (ranging from $6.00 to $14.00). Currently trading at $1.30, the median forecast implies a 592.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Harrison at Morgan Stanley, suggesting a 361.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IOBT Analyst Ratings
5
Buy
0
Hold
0
Sell
IOBT Price Target Range
Low
$6.00
Average
$9.00
High
$14.00
Current: $1.30
Latest IOBT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IOBT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 1, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Sep 16, 2024 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $6.00 |
| Sep 3, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $10.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Sep 3, 2024 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $4.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| May 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $12.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Sep 28, 2023 | Piper Sandler | Christopher Raymond | Overweight | Initiates | $10.00 |
| Sep 13, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Aug 15, 2023 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $7.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Mar 15, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $10.00 |
| Jan 24, 2023 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $11.00 |
| Nov 21, 2022 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $10.00 |
| Nov 30, 2021 | Cowen & Co. | Yaron Werber | Outperform | Initiates | $0.00 |
Io Biotech Inc. (IOBT) Competitors
The following stocks are similar to IO Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Io Biotech Inc. (IOBT) Financial Data
Io Biotech Inc. has a market capitalization of $85.65M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -138.8%.
Valuation Metrics
Market Cap
$85.65M
Enterprise Value
$51.64M
P/E Ratio
0.0x
PEG Ratio
-1.1x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+43.3%
Current Ratio
2.3x
Debt/Equity
6.7x
ROE
-138.8%
ROA
-70.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Io Biotech Inc. (IOBT) Business Model
About Io Biotech Inc.
What They Do
Develops immune-modulating cancer therapies.
Business Model
Io Biotech Inc. generates revenue through the development and commercialization of its proprietary immuno-oncology therapies. The company is engaged in clinical trials and research partnerships that enable it to advance its pipeline, aiming to bring innovative cancer treatments to market.
Additional Information
The company operates within the competitive biotechnology and pharmaceuticals industry, focusing on improving patient outcomes and addressing the demand for effective cancer treatments. Its unique platform is designed to selectively target cancer cells while preserving healthy tissue, positioning it as a leader in personalized health solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
79
CEO
Dr. Mai-Britt Zocca Ph.D.
Country
Denmark
IPO Year
2021
Website
www.iobiotech.comIo Biotech Inc. (IOBT) Latest News & Analysis
Latest News
Quick Summary
IO Biotech, Inc. (IOBT) has reached a key support level and experienced a "golden cross," with its 50-day moving average surpassing the 200-day average, indicating potential upward momentum.
Why It Matters
The "golden cross" indicates bullish momentum for IO Biotech, suggesting potential price appreciation, making it a favorable stock choice for technical traders.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IO Biotech (Nasdaq: IOBT) executives will participate in a virtual fireside chat at the TD Cowen Oncology Summit on May 27-28 and in one-on-one meetings at the Jefferies Global Healthcare Conference on June 3-5.
Why It Matters
Participation in major industry conferences by IO Biotech's leadership highlights their commitment to transparency and engagement, potentially influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IO Biotech expects Phase 3 trial results for its cancer vaccine IOB-013/KN-D18 in advanced melanoma by Q3 2025. The company was recognized for innovation and will present at upcoming conferences.
Why It Matters
The upcoming Phase 3 trial results for IO Biotech's cancer vaccine could significantly impact its stock price and market position, highlighting its innovative potential in oncology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IO Biotech (Nasdaq: IOBT) presented new preclinical data on its cancer vaccine candidates at the AACR Annual Meeting, highlighting their potential to enhance anti-tumor immunity.
Why It Matters
New preclinical data on IO Biotech's cancer vaccines could enhance their market position and attract investment, signaling potential breakthroughs in cancer treatment efficacy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IO Biotech's co-founder presented on cancer vaccines at the 2025 AACR Annual Meeting, highlighting advancements in research that may impact cancer immunotherapy.
Why It Matters
IO Biotech's participation in a key cancer vaccine session at a major conference highlights its role in advancing cancer immunotherapy, potentially boosting investor confidence and interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IO Biotech (Nasdaq: IOBT) announced new non-clinical data supporting IO102 and IO103's role in tumor control. Two abstracts will be presented at AACR Annual Meeting 2025, highlighting their potential in cancer treatment.
Why It Matters
Positive data on IO102 and IO103 enhances their potential as innovative cancer treatments, potentially leading to increased investor confidence and stock performance for IO Biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IOBT Stock
What is Io Biotech Inc.'s (IOBT) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Io Biotech Inc. (IOBT) has a median price target of $9.00. The highest price target is $14.00 and the lowest is $6.00.
Is IOBT stock a good investment in 2025?
According to current analyst ratings, IOBT has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IOBT stock?
Wall Street analysts predict IOBT stock could reach $9.00 in the next 12 months. This represents a 592.3% increase from the current price of $1.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Io Biotech Inc.'s business model?
Io Biotech Inc. generates revenue through the development and commercialization of its proprietary immuno-oncology therapies. The company is engaged in clinical trials and research partnerships that enable it to advance its pipeline, aiming to bring innovative cancer treatments to market.
What is the highest forecasted price for IOBT Io Biotech Inc.?
The highest price target for IOBT is $14.00 from at , which represents a 976.9% increase from the current price of $1.30.
What is the lowest forecasted price for IOBT Io Biotech Inc.?
The lowest price target for IOBT is $6.00 from Matthew Harrison at Morgan Stanley, which represents a 361.5% increase from the current price of $1.30.
What is the overall IOBT consensus from analysts for Io Biotech Inc.?
The overall analyst consensus for IOBT is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are IOBT stock price projections?
Stock price projections, including those for Io Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 11:03 PM UTC